Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.44)
# 1,137
Out of 4,581 analysts
163
Total ratings
42.1%
Success rate
14.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Maintained: Buy | $44 | $19.40 | +126.80% | 6 | Jul 23, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $91 | $60.06 | +51.52% | 7 | Jul 14, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $33.22 | +95.67% | 12 | Jul 11, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.39 | +259.71% | 12 | Jul 1, 2026 | |
| KOD Kodiak Sciences | Rated: Buy | $65 | $40.29 | +61.33% | 9 | Jun 29, 2026 | |
| IMMX Immix Biopharma | Initiated Coverage: Buy | $19 | $8.44 | +125.12% | 1 | Jun 17, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $45 | $11.06 | +307.06% | 9 | Jun 6, 2026 | |
| SLGL Sol-Gel Technologies | Maintained: Buy | $184 | $83.07 | +121.50% | 2 | May 28, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Buy | $12 | $3.14 | +282.17% | 44 | May 9, 2026 | |
| GPCR Structure Therapeutics | Rated: Buy | $107 → $104 | $47.89 | +117.16% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $58.95 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.83 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.7561 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $35.58 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $4.64 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €3.93 | n/a | 8 | Jun 16, 2020 |
Surrozen
Jul 23, 2026
Maintained: Buy
Price Target: $44
Current: $19.40
Upside: +126.80%
MBX Biosciences
Jul 14, 2026
Maintained: Buy
Price Target: $91
Current: $60.06
Upside: +51.52%
Neurogene
Jul 11, 2026
Maintained: Buy
Price Target: $65
Current: $33.22
Upside: +95.67%
iBio, Inc.
Jul 1, 2026
Maintained: Buy
Price Target: $5
Current: $1.39
Upside: +259.71%
Kodiak Sciences
Jun 29, 2026
Rated: Buy
Price Target: $65
Current: $40.29
Upside: +61.33%
Immix Biopharma
Jun 17, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $8.44
Upside: +125.12%
Oculis Holding AG
Jun 6, 2026
Maintained: Buy
Price Target: $45
Current: $11.06
Upside: +307.06%
Sol-Gel Technologies
May 28, 2026
Maintained: Buy
Price Target: $184
Current: $83.07
Upside: +121.50%
Rocket Pharmaceuticals
May 9, 2026
Rated: Buy
Price Target: $12
Current: $3.14
Upside: +282.17%
Structure Therapeutics
May 9, 2026
Rated: Buy
Price Target: $107 → $104
Current: $47.89
Upside: +117.16%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $58.95
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.83
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.7561
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $35.58
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $4.64
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €3.93
Upside: n/a